S
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. Founded in 2017, SpringWorks has a diversified targeted oncology pipeline spanning solid tumors and hematological cancers, including clinical trials in rare tumor types and highly prevalent, genetically defined cancers.
Investor insights
Funding rounds participated in
$275M sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2017
Funding rounds raised
Total raised
$275M
from investors over 1 rounds
S
SpringWorks Therapeutics raised $275M on January 5, 2024